GlassScriptPhysician profile
Elcy M John
NPI 1083611628
$2,167.03
in general payments reported to CMS, 2019-2025
29 companies · $163 in 2025
The $163 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $247 · 2021: $415 · 2022: $300 · 2023: $467 · 2024: $199 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $828.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $239.72 | 2023 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $213.59 | 2019-2023 | |
| Myovant Sciences INC. | $204.69 | 2021-2022 | |
| Agile Therapeutics, INC. | $193.75 | 2021-2024 | Twirla |
| Hologic Sales and Service, LLC | $192.18 | 2019-2025 | Aptima, Acessa Provu System, Thinprep 2000 Processor |
| Abbvie INC. | $179.79 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $125.61 | 2019-2023 | Gardasil 9 |
| Avanos Medical | $120.94 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $84.86 | 2021-2025 | |
| Organon LLC | $65.13 | 2021-2022 | |
| Biogen, INC. | $56.05 | 2024 | Zurzuvae |
| Roche Diagnostics Corporation | $47.42 | 2019 | |
| Coopersurgical, INC. | $45.61 | 2019-2022 | |
| Pfizer INC. | $41.58 | 2023-2024 | |
| Aspira Women'S Health INC | $41.00 | 2020-2024 | Ova1 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $39.12 | 2021-2022 | |
| Dexcom, INC. | $34.04 | 2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $33.31 | 2019 | |
| Millicent US INC | $32.79 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $25.14 | 2022 | |
| Mylan Pharmaceuticals INC. | $24.63 | 2019-2022 | |
| Abbott Laboratories | $21.14 | 2022 | |
| Gynesonics, INC. | $18.11 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Pacira Pharmaceuticals Incorporated | $16.43 | 2021 | |
| Acessa Health INC. | $15.94 | 2019 | |
| Exeltis, USA INC. | $15.85 | 2021 | |
| Astellas Pharma US INC | $14.93 | 2020 | |
| Allergan, INC. | $12.42 | 2019 | |
| Renovia INC | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elcy John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.